GRFS Stock - Grifols, S.A.
Unlock GoAI Insights for GRFS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.21B | $6.59B | $6.06B | $4.93B | $5.34B |
| Gross Profit | $2.79B | $2.48B | $2.21B | $1.96B | $2.26B |
| Gross Margin | 38.7% | 37.7% | 36.5% | 39.8% | 42.2% |
| Operating Income | $1.19B | $782.32M | $782.44M | $595.06M | $996.13M |
| Net Income | $156.92M | $42.32M | $185.03M | $188.73M | $618.55M |
| Net Margin | 2.2% | 0.6% | 3.1% | 3.8% | 11.6% |
| EPS | $0.23 | $0.09 | $0.31 | $0.27 | $0.73 |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 12th 2025 | Morgan Stanley | Resumed | Overweight | - |
| March 12th 2024 | Deutsche Bank | Downgrade | Sell | - |
| April 12th 2023 | Morgan Stanley | Upgrade | Overweight | - |
| March 3rd 2023 | Morgan Stanley | Downgrade | Equal Weight | - |
| February 16th 2023 | Barclays | Upgrade | Equal Weight | - |
| January 18th 2023 | Jefferies | Upgrade | Buy | - |
| April 11th 2022 | Morgan Stanley | Initiation | Equal Weight | - |
Earnings History & Surprises
GRFSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.24 | $0.22 | -9.6% | ✗ MISS |
Q3 2025 | Jul 28, 2025 | $0.23 | $0.19 | -17.4% | ✗ MISS |
Q2 2025 | May 12, 2025 | $0.14 | $0.10 | -28.6% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $0.13 | $0.26 | +100.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.22 | $0.16 | -27.3% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $0.23 | $0.02 | -91.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $0.15 | $0.07 | -53.3% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $0.22 | $0.14 | -36.4% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $0.22 | $0.11 | -50.0% | ✗ MISS |
Q3 2023 | Jul 27, 2023 | $0.20 | $0.09 | -54.8% | ✗ MISS |
Q2 2023 | May 16, 2023 | $0.16 | $-0.02 | -110.7% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $0.24 | $0.03 | -86.7% | ✗ MISS |
Q1 2023 | Feb 27, 2023 | $0.24 | $0.06 | -73.3% | ✗ MISS |
Q3 2022 | Jul 28, 2022 | $0.29 | $0.14 | -52.3% | ✗ MISS |
Q2 2022 | May 5, 2022 | — | — | — | — |
Q1 2022 | Feb 28, 2022 | $0.24 | $-0.13 | -155.1% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $0.36 | — | — |
Q3 2021 | Jul 29, 2021 | $0.27 | $0.35 | +29.6% | ✓ BEAT |
Latest News
CORRECTION: JP Morgan Maintains Neutral on Grifols, Maintains $10 Price Target (Price Target Updated - Rating Originally Published on 8th Dec)
➖ NeutralJP Morgan Maintains Neutral on Grifols, Lowers Price Target to $10
➖ NeutralGrifols Achieved Clinical Self-Sufficiency In Egypt For Immunoglobulins, Albumin, And Coagulation Factors Through Grifols Egypt For Plasma Derivatives
📈 PositiveFrequently Asked Questions about GRFS
What is GRFS's current stock price?
What is the analyst price target for GRFS?
What sector is Grifols, S.A. in?
What is GRFS's market cap?
Does GRFS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GRFS for comparison